Technology platforms for pharmacogenomic diagnostic assays.
Rapid advances in the understanding of genomic variation affecting drug responses, and the development of multiplex assay technologies, are converging to form the basis for new in vitro diagnostic assays. These molecular diagnostic assays are expected to guide the therapeutic treatment of many diseases, by informing physicians about molecular subtypes of disease that require differential treatment, which drug has the greatest probability of effectively managing the disease, and which individual patients are at the highest risk of experiencing adverse reactions to a given drug therapy. This article reviews some of the relative strengths and limitations of the most widely used technologies and platforms for such assays.
Koch
Walter H
WH
Roche Molecular Systems, Pharmacogenetics Department, 4300 Hacienda Drive, Pleasanton, California 94588, USA. walter_h.koch@roche.com
D000818:Animals; D003933:Diagnosis; D005819:Genetic Markers; D005838:Genotype; D006801:Humans; D008495:Medical Oncology / Q000639:trends; D020411:Oligonucleotide Array Sequence Analysis; D010597:Pharmacogenetics / Q000295:instrumentation*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D020539:Sequence Analysis, Protein
D005819:Genetic Markers